WMS-1410

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 465933

CAS#: unknown

Description: WMS-1410 is a novel GluN2B-specific NMDAR antagonist, completely preventing the decrease in insulin secretion of about 32 % provoked by a 24-h-treatment with NMDA/glycine, eliminating NMDA-induced changes in the oxidation status of the islet cells and elevating the sensitivity of intracellular calciumto 15 mM glucose.


Chemical Structure

img
WMS-1410
CAS# unknown

Theoretical Analysis

MedKoo Cat#: 465933
Name: WMS-1410
CAS#: unknown
Chemical Formula: C20H25NO2
Exact Mass: 311.19
Molecular Weight: 311.425
Elemental Analysis: C, 77.14; H, 8.09; N, 4.50; O, 10.27

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: WMS-1410; WMS1410; WMS 1410;

IUPAC/Chemical Name: 3-(4-phenylbutyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine-1,7-diol

InChi Key: KKLZGWQBNXJWGZ-UHFFFAOYSA-N

InChi Code: InChI=1S/C20H25NO2/c22-18-9-10-19-17(14-18)11-13-21(15-20(19)23)12-5-4-8-16-6-2-1-3-7-16/h1-3,6-7,9-10,14,20,22-23H,4-5,8,11-13,15H2

SMILES Code: OC1CN(CCCCC2=CC=CC=C2)CCC3=CC(O)=CC=C13

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 311.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Markus A, Schepmann D, Wünsch B. Synthesis of oxazolo-annulated 3-benzazepines designed by merging two negative allosteric NMDA receptor modulators. Arch Pharm (Weinheim). 2022 Feb 27:e2200020. doi: 10.1002/ardp.202200020. Epub ahead of print. PMID: 35224754.

2: Gresch A, Hurtado HN, Wörmeyer L, De Luca V, Wiggers R, Seebohm G, Wünsch B, Düfer M. Selective Inhibition of N-Methyl-d-aspartate Receptors with GluN2B Subunit Protects β Cells against Stress-Induced Apoptotic Cell Death. J Pharmacol Exp Ther. 2021 Nov;379(3):235-244. doi: 10.1124/jpet.121.000807. Epub 2021 Sep 30. PMID: 34593560.

3: Ritter N, Korff M, Markus A, Schepmann D, Seebohm G, Schreiber JA, Wünsch B. Deconstruction - Reconstruction: Analysis of the Crucial Structural Elements of GluN2B-Selective, Negative Allosteric NMDA Receptor Modulators with 3-Benzazepine Scaffold. Cell Physiol Biochem. 2021 Mar 3;55(S3):1-13. doi: 10.33594/000000335. PMID: 33656308.

4: Falck E, Begrow F, Verspohl EJ, Wünsch B. In vitro and in vivo biotransformation of WMS-1410, a potent GluN2B selective NMDA receptor antagonist. J Pharm Biomed Anal. 2014 Jun;94:36-44. doi: 10.1016/j.jpba.2014.01.017. Epub 2014 Jan 24. PMID: 24534302.

5: Tewes B, Frehland B, Schepmann D, Schmidtke KU, Winckler T, Wünsch B. Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols. Bioorg Med Chem. 2010 Nov 15;18(22):8005-15. doi: 10.1016/j.bmc.2010.09.026. Epub 2010 Sep 24. PMID: 20965739.